Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR; HORIZON Pivotal Fracture Trial.

N Engl J Med. 2007 May 3;356(18):1809-22.

2.

[Fracture prevention in postmenopausal women with osteoporosis by an annual infusion of zoledronic acid].

Geusens PP, Lems WF.

Ned Tijdschr Geneeskd. 2007 Jun 30;151(26):1445-8. Dutch.

PMID:
17633971
3.

Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older.

Boonen S, Black DM, Colón-Emeric CS, Eastell R, Magaziner JS, Eriksen EF, Mesenbrink P, Haentjens P, Lyles KW.

J Am Geriatr Soc. 2010 Feb;58(2):292-9. doi: 10.1111/j.1532-5415.2009.02673.x. Epub 2010 Jan 8.

4.

Zoledronic acid and clinical fractures and mortality after hip fracture.

Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S; HORIZON Recurrent Fracture Trial.

N Engl J Med. 2007 Nov 1;357(18):1799-809. doi: 10.1056/NEJMoa074941. Epub 2007 Sep 17.

5.

Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.

Liang BC, Shi ZY, Wang B, Wu P, Kong LC, Yao JL, Li CW, Shi XL.

Orthop Surg. 2017 Feb;9(1):103-109. doi: 10.1111/os.12307. Epub 2017 Mar 9.

PMID:
28276638
6.

Fracture risk and zoledronic acid therapy in men with osteoporosis.

Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J, Langdahl B, Rizzoli R, Lipschitz S, Dimai HP, Witvrouw R, Eriksen E, Brixen K, Russo L, Claessens F, Papanastasiou P, Antunez O, Su G, Bucci-Rechtweg C, Hruska J, Incera E, Vanderschueren D, Orwoll E.

N Engl J Med. 2012 Nov 1;367(18):1714-23. doi: 10.1056/NEJMoa1204061.

7.
8.

Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study.

Matsumoto T, Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Morii H, Ohashi Y, Nakamura T.

Osteoporos Int. 2009 Aug;20(8):1429-37. doi: 10.1007/s00198-008-0816-7. Epub 2008 Dec 20.

9.

The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis.

Hwang JS, Chin LS, Chen JF, Yang TS, Chen PQ, Tsai KS, Leung PC.

J Bone Miner Metab. 2011 May;29(3):328-33. doi: 10.1007/s00774-010-0223-y. Epub 2010 Oct 5.

PMID:
20922438
10.

Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.

Woodis CB.

Ann Pharmacother. 2008 Jul;42(7):1085-9. doi: 10.1345/aph.1K652. Epub 2008 May 27.

PMID:
18505912
11.

[Evidences of safety and tolerability of the zoledronic acid 5 mg yearly in the post-menopausal osteoporosis: the HORIZON project].

Dalle Carbonare L, Bertoldo F, Lo Cascio V.

Reumatismo. 2009 Jan-Mar;61(1):54-64. Italian.

12.

Intravenous zoledronic acid in postmenopausal women with low bone mineral density.

Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier PJ.

N Engl J Med. 2002 Feb 28;346(9):653-61.

13.

Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C; FREEDOM Trial.

N Engl J Med. 2009 Aug 20;361(8):756-65. doi: 10.1056/NEJMoa0809493. Epub 2009 Aug 11. Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914.

14.

Zoledronic acid: a review of its use in the treatment of osteoporosis.

Deeks ED, Perry CM.

Drugs Aging. 2008;25(11):963-86. doi: 10.2165/0002512-200825110-00007. Review.

PMID:
18947264
15.

Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women.

Lambrinoudaki I, Vlachou S, Galapi F, Papadimitriou D, Papadias K.

Clin Interv Aging. 2008;3(3):445-51. Review.

16.

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.

Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S.

J Bone Miner Res. 2011 Mar;26(3):503-11. doi: 10.1002/jbmr.238.

17.

Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture.

Eriksen EF, Lyles KW, Colón-Emeric CS, Pieper CF, Magaziner JS, Adachi JD, Hyldstrup L, Recknor C, Nordsletten L, Lavecchia C, Hu H, Boonen S, Mesenbrink P.

J Bone Miner Res. 2009 Jul;24(7):1308-13. doi: 10.1359/jbmr.090209.

18.

Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.

McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.

Bone. 2007 Jul;41(1):122-8. Epub 2007 Mar 24.

PMID:
17468062
19.

Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density.

Eastell R, Black DM, Boonen S, Adami S, Felsenberg D, Lippuner K, Cummings SR, Delmas PD, Palermo L, Mesenbrink P, Cauley JA; HORIZON Pivotal Fracture Trial.

J Clin Endocrinol Metab. 2009 Sep;94(9):3215-25. doi: 10.1210/jc.2008-2765. Epub 2009 Jun 30.

20.

Single annual injectable treatment for postmenopausal osteoporosis.

Chapurlat RD.

Expert Opin Drug Deliv. 2008 May;5(5):583-91. doi: 10.1517/17425247.5.5.583 . Review.

PMID:
18491983

Supplemental Content

Support Center